Can an immune booster stop serious infections in blood cancer patients?
NCT ID NCT07582432
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether adding Gamunex-C (an immune globulin) to standard care can prevent serious infections in people with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma. About 49 participants will receive Gamunex-C through an IV every 4 weeks for a year. The main goal is to see if the rate of serious bacterial infections drops.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gamunex-C (immune globulin injection)
What this could lead to
If it works, this could provide a way to reduce serious infections in people with blood cancers who have weakened immune systems.
What could go wrong
This is a small, single-arm trial with no placebo group, so results may be less reliable. Side effects from Gamunex-C can include headache, fever, and allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA, MULTIPLE MYELOMA, OR NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Study Site 101
RECRUITINGFort Wayne, Indiana, 46894, United States
Contact Email: •••••@•••••
-
Study Site 102
NOT_YET_RECRUITINGSt. Petersburg, Florida, 33709, United States
Contact Email: •••••@•••••
-
Study Site 103
NOT_YET_RECRUITINGTacoma, Washington, 98405, United States
Contact Email: •••••@•••••
-
Study Site 104
NOT_YET_RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
-
Study Site 105
NOT_YET_RECRUITINGWestbrook, Maine, 04092, United States
Contact Email: •••••@•••••